Endocrine Abstracts

Introduction: The Warthin-like variant of papillary thyroid cancer (WLPTC) is a rare subtype of papillary thyroid carcinoma (PTC) resembling Warthin tumours of the salivary glands, and more commonly associated with Hashimoto’s thyroiditis than other types of PTCs. The WLPTC is characterized by papillae lined by large oncocytic cells with cores having dense lymphoplasmacytic infiltrate. The prognosis of WLPTC is the same or less aggressive than that of classical PTC, but i...

Background: Medullary thyroid cancer (MTC) is a rare malignancy with a variable and sometimes unpredictable disease course. To predict the course of disease more accurately at diagnosis, we introduce dynamic risk stratification by analyzing factors related to “stage migration” within the first 5 years after diagnosis.Methods: All patients diagnosed at the University Medical Center of Groningen between 1999 and 2015 were retrospectively studied....

Background: Lymph node metastases at histology (pN1) are usual findings in differentiated thyroid cancer (DTC) patients. Their detection has an impact on the extent of surgery, the further treatments after surgery, and on the clinical outcome.Material and method: We evaluated data of 1332 consecutive DTC patients who performed the first 131I treatment between January 2010 and September 2012. According to their pN status, they were divided into...

Background: Human cancer is characterized by the accumulation of somatic alterations including base substitutions, indels, structural rearrangements and somatic copy number alteration (CNA), either gain or loss, of chromosomes that can be responsible either for initiation and/or cancer progression. About 80% of Sporadic Medullary Thyroid Carcinoma (sMTC) harbor RET or RAS somatic alterations with a negative prognostic role for the presence of the RET mutation; a few s...

Objectives: Image-guided thermal-ablation (LTA; RFA) are well established therapy options in selected BTN. PMWT is a mini-invasive technique recently applied in thyroid disease; aim of this work is investigate its effectiveness as treatment in BTN.Methods: From May 2021, 45 patients (30 F, 15 M, Aged 37-90, Mean 55,8) with BTN symptomatic/in growing, refusing/non eligible to surgery were enrolled. Inclusion criteria: nodule diameter ≥ 2 cm, mainly ...

Background: Medullary thyroid carcinoma (MTC) is a rare disease accounting for 1-3% of all thyroid carcinomas. Unfortunately, most patients present with metastasized disease: 70% with cervical lymph node metastasis and 5-10% with distant metastasis. Survival strongly correlates with stage of disease at diagnosis, illustrating the need for early diagnosis. Calcitonin is a well-established tumour marker for MTC, but its use in the screening phase is limited by a high rate of fal...

In the last decades, multi-tyrosine-kinase inhibitors (mTKI) have emerged as an effective treatment for radioiodine refractory differentiated thyroid cancer. Due to their pleiotropic mechanism of action, these drugs may cause different side effects. Hypocalcaemia has been reported in up to 35% of patients treated with mTKI, but up to date little is known about its pathophysiology and relevance. We report the case of a 78 years old woman operated on for a papillary thyroid canc...

Introduction: Medullary thyroid cancer (MTC) is a rare thyroid malignacy whоsе prognosis is highly dependent on the early diagnosis as well as on the available treatment options. Serum calcitonin represents the most sensitive test for the detection of MTC thus its measurement is strongly recommended in patients with known genetic or hereditary conditions associated with high risk of medullary hyperplasia or cancer. However, its diagnostic utility and routine clinical ...

Introduction: Medullary thyroid carcinoma (MTC) is a calcitonin-producing tumor that predominantly occurs in a sporadic form (75%) and less commonly in an inherited form. Besides activating germline mutations of the RET proto-oncogene in hereditary syndromes of MEN2, somatic RET mutations are detectable in about 50% of sporadic MTC. Further, also RAS mutations have been discovered in 30% of RET-negative tumor tissues. Other genetic alteratio...

Introduction: Treatment of differentiated thyroid carcinoma (DTC) remains a challenge in the setting of locally advanced or metastatic disease refractory to radiodine (RAI) therapy. SELECT trial demonstrated that Lenvatinib improved progression free survival (PFS) comparing to placebo.Objective: Our aim is to report the efficacy and safety of lenvatinib in our population with aggressive DTC.Methods: We retrospectively reviewed the ...